Square-wave action dystonia in Parkinson's disease.
van den Munckhof
P
P
Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1406, USA.
Lenz
F A
FA
Chase
T N
TN
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects*; D004292:Dominance, Cerebral / Q000187:drug effects / Q000502:physiology; D004338:Drug Combinations; D004421:Dystonia / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology / Q000601:surgery; D005917:Globus Pallidus / Q000187:drug effects / Q000503:physiopathology / Q000601:surgery; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D010300:Parkinson Disease / Q000175:diagnosis* / Q000503:physiopathology / Q000601:surgery
D000978:Antiparkinson Agents; D004338:Drug Combinations; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D002230:Carbidopa